# Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

> **NCT00163748** · PHASE2 · COMPLETED · sponsor: **Bayside Health** · enrollment: 40 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma
- Hodgkin's Disease

## Interventions

- **DRUG:** gemcitabine, vinorelbine

## Key facts

- **NCT ID:** NCT00163748
- **Lead sponsor:** Bayside Health
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 40 (—)
- **Last updated:** 2016-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00163748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00163748, "Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00163748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*